☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Insulin detemir weight advantage in type 1 diabetes

The manufacturer has insulin detemir (Levemir®) has announced that previously observed weight benefits extend to 2 years in patients with type 1 diabetes. PharmaTimes has reported this finding following presentation of the results at the Annual Meeting of the European Association for the Study of Diabetes (EASD).

The study was a 2 year open-label study in 497 patients with type 1 diabetes comparing insulin detemir with NHP insulin. Both groups were also treated with short acting insulin at mealtimes.

In patients who were treated with insulin detemir:

  • Average HbA1c was lower (7.36% versus 7.58%)
  • More patients reached a HbA1c target of <7% (22% versus 13%; p = 0.019)
  • Were at 69% less risk of major hypoglycaemia
  • Were at 46% less risk of nocturnal hypoglycaemia
  • Weight gain was reduced (1.7kg versus 2.7kg; p=0.024)

While these are interesting results it should be noted that this study relates to patients with type 1 diabetes and may not be applicable to patients with type 2 diabetes.

Action: Clinicians should be aware of this study but take care to ensure that the results are not automatically applied to patients with type 2 diabetes.

Share 'Insulin detemir weight advantage in type 1 diabetes' by emailShare 'Insulin detemir weight advantage in type 1 diabetes' on FacebookShare 'Insulin detemir weight advantage in type 1 diabetes' on TwitterShare 'Insulin detemir weight advantage in type 1 diabetes' on MastodonShare 'Insulin detemir weight advantage in type 1 diabetes' on LinkedInShare 'Insulin detemir weight advantage in type 1 diabetes' on reddit

atomic-wealth

No Comments to “Insulin detemir weight advantage in type 1 diabetes”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.